Products
Nabumetone was commercially available in many countries in the form of film-coated tablets and soluble tablets (Balmox). It was approved in 1992 and went out of commerce in 2013, presumably for commercial reasons.
Structure and properties
Nabumetone (C15H16O2, Mr = 228.3 g/mol) exists as a white crystalline powder that is practically insoluble in water. Structurally, it is a naphthylalkanone. Nabumetone, unlike other NSAIDs, does not exist as an acid, but is metabolized to one. It is a prodrug and is biotransformed in the liver to the active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA, Figure).
Effects
Nabumetone (ATC M01AX01) is analgesic, antipyretic, and anti-inflammatory. The effects are due to inhibition of prostaglandin synthesis. Nabumetone is relatively selective for cyclooxygenase-2.
Indications
For the treatment of painful and inflammatory conditions, e.g., rheumatoid arthritis, osteoarthritis, sports injuries.
Dosage
According to the SmPC. The tablets need to be taken only once or twice daily, preferably during a meal, because of the long half-life.
Contraindications
Numerous precautions must be observed during use. Full details of precautions and drug interactions can be found in the Drug Information Leaflet.
Adverse effects
The most common possible adverse effects include diarrhea, dyspepsia, stomach or abdominal pain, and other digestive disorders, rash, pruritus, headache, dizziness, fatigue, drowsiness, insomnia, visual disturbances, ringing in the ears, and edema. As with all NSAIDs, serious side effects such as cardiovascular disease, kidney disease, and stomach or intestinal ulcers are rare.
